PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response

Journal of Clinical Investigation

Volumn 125, Issue 12, 2015, Pages 4529-4543

  Liao, Hsin Wei ^a,b   Hsu, Jung Mao ^a   Xia, Weiya ^a   Wang, Hung Ling ^c   Wang, Ying Nai ^a,c,d   Chang, Wei Chao ^c   Arold, Stefan T ^a,e   Chou, Chao Kai ^a,c   Tsou, Pei Hsiang ^a   Yamaguchi, Hirohito ^a   Fang, Yueh Fu ^a,f   Lee, Hong Jen ^a,b   Lee, Heng Huan ^a   Tai, Shyh Kuan ^g   Yang, Mhu Hwa ^h   Morelli, Maria P ^a   Sen, Malabika ⁱ   Ladbury, John E ^a,j   Chen, Chung Hsuan ^k   Grandis, Jennifer R ^i,l   Kopetz, Scott ^a   Hung, Mien Chie ^a,b,c,d   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k GENOMICS RESEARCH CENTER   (Taiwan)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PRMT1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; DIMERIZATION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; METHYLATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; RECURRENCE RISK; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CETUXIMAB; COLONIC NEOPLASMS; FEMALE; HETEROGRAFTS; HUMANS; METHYLATION; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEIN-ARGININE N-METHYLTRANSFERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 84948798342     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82826     Document Type: Article

References (60)

1. Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des. 2012;18(19):2672-2679.
2. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int. 2013;2013:546318.
3. Hsu JM, et al. Crosstalk between Arg 1175 meth-ylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol. 2011;13(2):174-181.
4. Nguyen LK, Kolch W, Kholodenko BN. When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal. 2013;11:52.
5. Bishayee S. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function. Biochem Pharmacol. 2000;60(8):1217-1223.
6. Ishikawa HO, Takeuchi H, Haltiwanger RS, Irvine KD. Four-jointed is a Golgi kinase that phospho-rylates a subset of cadherin domains. Science. 2008;321(5887):401-404.
7. Yalak G, Vogel V. Extracellular phosphorylation and phosphorylated proteins: not just curiosities but physiologically important. Sci Signal. 2012;5(255):re7.
8. Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab. 2010;36(6 pt 1):423-435.
9. Yoshimatsu M, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011;128(3):562-573.
10. Yang Y, Bedford MT. Protein arginine methyl-transferases and cancer. Nat Rev Cancer. 2013;13(1):37-50.
11. Cha B, Jho EH. Protein arginine methyltransfer-ases (PRMTs) as therapeutic targets. Expert Opin Ther Targets. 2012;16(7):651-664.
12. Wei H, Mundade R, Lange KC, Lu T. Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle. 2014;13(1):32-41.
13. Cheng L, et al. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol. 2014;74(1):1-13.
14. Funakoshi T, Latif A, Galsky MD. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev. 2014;40(5):636-647.
15. Krawczyk PA, Kowalski DM. Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Con-temp Oncol (Pozn). 2014;18(1):7-16.
16. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol. 2013;85(1):45-81.
17. Lievre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26(3):374-379.
18. De Roock W, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515.
19. Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
20. Bokemeyer C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
21. Morton RF, Hammond EH. ASCO provisional clinical opinion: KRAS, Cetuximab, and Panitu-mumab-clinical implications in colorectal cancer. J Oncol Pract. 2009;5(2):71-72.
22. Laurent-Puig P, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuxi-mab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009;27(35):5924-5930.
23. Fabian P, Berkovcova J. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]. Cesk Patol. 2011;47(4):154-158.
24. Silvestris N, et al. KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in meta-static colorectal carcinoma: an open issue. Expert Opin Biol Ther. 2009;9(5):565-577.
25. Messner I, et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol. 2013;139(2):201-209.
26. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer. 2013;119(4):714-721.
27. Tejpar S, Celik I, Schlichting M, Sartorius U, Boke-meyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuxi-mab. J Clin Oncol. 2012;30(29):3570-3577.
28. De Roock W, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic col-orectal cancer treated with cetuximab. JAMA. 2010;304(16):1812-1820.
29. Boisvert FM, Rhie A, Richard S, Doherty AJ. The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity. Cell Cycle. 2005;4(12):1834-1841.
30. Yu Z, et al. The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation. Cell Res. 2012;22(2):305-320.
31. Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008;68(10):3803-3809.
32. Cheng D, Yadav N, King RW, Swanson MS, Wein-stein EJ, Bedford MT. Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004;279(23):23892-23899.
33. Hassdenteufel S, Klein MC, Melnyk A, Zimmermann R. Protein transport into the human ER and related diseases, Sec61-channelopathies. Biochem Cell Biol. 2014;92(6):499-509.
34. Scorilas A, Black MH, Talieri M, Diamandis EP. Genomic organization, physical mapping, and expression analysis of the human protein argin-ine methyltransferase 1 gene. Biochem Biophys Res Commun. 2000;278(2):349-359.
35. Troiani T, et al. Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 2013;19(24):6751-6765.
36. Herrmann F, Fackelmayer FO. Nucleo-cytoplas-mic shuttling of protein arginine methyltransfer-ase 1 (PRMT1) requires enzymatic activity. Genes Cells. 2009;14(3):309-317.
37. Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. Br J Cancer. 2008;99(12):2094-2099.
38. Ogiso H, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110(6):775-787.
39. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon M.A. EGF activates its receptor by removing interactions that auto-inhibit ectodomain dimerization. Mol Cell. 2003;11(2):507-517.
40. Alvarado D, Klein DE, Lemmon M.A. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature. 2009;461(7261):287-291.
41. Alvarado D, Klein DE, Lemmon M.A. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell. 2010;142(4):568-579.
42. Chung I, Akita R, Vandlen R, Toomre D, Schless-inger J, Mellman I. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 2010;464(7289):783-787.
43. Partridge EA, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocyto-sis. Science. 2004;306(5693):120-124.
44. Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs. 2007;67(17):2585-2607.
45. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009;158(1):1-9.
46. Bou-Assaly W, Mukherji S. Cetuximab (erbitux). AJNR Am J Neuroradiol. 2010;31(4):626-627.
47. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuxi-mab. Cancer Cell. 2005;7(4):301-311.
48. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
49. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201-1208.
50. Vallbohmer D, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005;23(15):3536-3544.
51. van Houdt WJ, et al. Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. Neopla-sia. 2010;12(6):443-452.
52. Hsieh YY, Tzeng CH, Chen MH, Chen PM, Wang WS. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci. 2012;103(4):791-796.
53. Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol. 1994;14(6):3535-3549.
54. Ibar C, Orellana A. The import of S-adenosyl-methionine into the Golgi apparatus is required for the methylation of homogalacturonan. Plant Physiol. 2007;145(2):504-512.
55. Wu CC, et al. Organellar proteomics reveals Golgi arginine dimethylation. Mol Biol Cell. 2004;15(6):2907-2919.
56. Poulard C, Rambaud J, Hussein N, Corbo L, Le Romancer M. JMJD6 regulates ERalpha methyla-tion on arginine. PLoS One. 2014;9(2):e87982.
57. Le Romancer M, et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell. 2008;31(2):212-221.
58. Sylvestersen KB, Horn H, Jungmichel S, Jensen LJ, Nielsen ML. Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest. Mol Cell Proteomics. 2014;13(8):2072-2088.
59. Cho EC, et al. Arginine methylation controls growth regulation by E2F-1. EMBO J. 2012;31(7):1785-1797.
60. Rahimi N, Costello CE. Emerging roles of post-translational modifications in signal transduction angiogenesis. Proteomics. 2014;15(2-3):300-309.